ImmunityBio (IBRX) Income towards Parent Company (2014 - 2026)
ImmunityBio (IBRX) reported Income towards Parent Company of -$632.8 million for Q1 2026, down 387.89% year-over-year from $219.8 million in Q1 2025, and down 921.33% on a QoQ basis from -$62.0 million in Q4 2025.
ImmunityBio (IBRX) has 13 years of Income towards Parent Company data on file, last reported at -$632.8 million in Q1 2026.
- Quarterly Income towards Parent Company fell 387.89% year-over-year to -$632.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$854.6 million (down 108.85% YoY) and the FY2025 annual result came in at -$351.5 million, up 15.03% from the prior year.
- Income towards Parent Company slipped to -$632.8 million in Q1 2026 per IBRX's latest filing, from -$62.0 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$59.2 million in Q4 2024 and bottomed at -$632.8 million in Q1 2026.
- The 5-year median for Income towards Parent Company is -$108.3 million (2022), against an average of -$141.1 million.
- The widest annual swing landed in 2024, when Income towards Parent Company jumped 74.65%; it then slumped 387.89% in 2026.
- Tracing IBRX's Income towards Parent Company over 5 years: stood at -$108.3 million in 2022, then plunged by 115.47% to -$233.4 million in 2023, then jumped by 74.65% to -$59.2 million in 2024, then dropped by 4.7% to -$62.0 million in 2025, then tumbled by 921.33% to -$632.8 million in 2026.
- Per Business Quant, the three latest IBRX Income towards Parent Company figures stand at -$632.8 million (Q1 2026), -$62.0 million (Q4 2025), and -$67.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | ImmunityBio | 7.72 Bn | 7.34 Bn | 43.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -632.80 Mn |
| Dec 31, 2025 | -61.96 Mn |
| Sep 30, 2025 | -67.27 Mn |
| Jun 30, 2025 | -92.61 Mn |
| Mar 31, 2025 | -129.70 Mn |
| Dec 31, 2024 | -59.18 Mn |
| Sep 30, 2024 | -85.75 Mn |
| Jun 30, 2024 | -134.58 Mn |
| Mar 31, 2024 | -134.13 Mn |
| Dec 31, 2023 | -233.41 Mn |
| Sep 30, 2023 | -95.64 Mn |
| Jun 30, 2023 | -138.21 Mn |
| Mar 31, 2023 | -116.58 Mn |
| Dec 31, 2022 | -108.33 Mn |
| Sep 30, 2022 | -111.16 Mn |
| Jun 30, 2022 | -94.84 Mn |
| Mar 31, 2022 | -103.00 Mn |
| Dec 31, 2021 | -91.55 Mn |
| Sep 30, 2021 | -88.43 Mn |
| Jun 30, 2021 | -89.39 Mn |
| Mar 31, 2021 | -80.48 Mn |
| Dec 31, 2020 | -68.57 Mn |
| Sep 30, 2020 | -66.17 Mn |
| Jun 30, 2020 | -52.02 Mn |
| Mar 31, 2020 | -37.43 Mn |
| Dec 31, 2019 | -110.01 Mn |
| Sep 30, 2019 | -15.58 Mn |
| Jun 30, 2019 | -16.68 Mn |
| Mar 31, 2019 | -17.89 Mn |
| Dec 31, 2018 | 76.58 Mn |
| Sep 30, 2018 | -23.64 Mn |
| Jun 30, 2018 | -27.73 Mn |
| Mar 31, 2018 | -27.52 Mn |
| Dec 31, 2017 | -24.49 Mn |
| Sep 30, 2017 | -23.97 Mn |
| Jun 30, 2017 | -23.45 Mn |
| Mar 31, 2017 | -24.52 Mn |
| Dec 31, 2016 | -24.24 Mn |
| Sep 30, 2016 | -31.90 Mn |
| Jun 30, 2016 | -34.00 Mn |
| Mar 31, 2016 | -30.68 Mn |
| Dec 31, 2015 | 208.63 Mn |
| Sep 30, 2015 | -46.31 Mn |
| Jun 30, 2015 | -130.89 Mn |
| Mar 31, 2015 | -32.85 Mn |
| Dec 31, 2014 | -2.74 Mn |
| Sep 30, 2014 | -896,000.00 |
| Jun 30, 2014 | -1.40 Mn |
| Mar 31, 2014 | -826,000.00 |